Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INDV-2000 · IDV-184001

Small molecule · Antagonist of orexin 1 receptor (HCRTR1) · developed by Indivior

Phase 2 Most advanced trial (none active)
1 Registered trials

What is INDV-2000?

INDV-2000 (also known as IDV-184001) is a highly potent and selective orexin 1 receptor (OX1R) antagonist. It is being studied for the treatment of opioid use disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IDV-184001
Drug type
Small molecule
Targets
orexin 1 receptor (HCRTR1)
Mechanism
Antagonist of orexin 1 receptor (HCRTR1)
Therapy area
Psychiatry
Developer
Indivior Inc.
In trials of
INDV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
8RJN30TJM6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06384157 Phase 2 Opioid Use Disorder Completed INDV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Opioid Use Disorder

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.